News >

Genomic Testing Puts Myeloma Paradigm on Personalized Path

Ellie Leick
Published: Friday, Aug 30, 2019

Samir Parekh, MD

Samir Parekh, MD

The perception of multiple myeloma is changing, as researchers have discovered that what was once thought of as one disease is actually quite heterogenic, adding a greater need for genomic testing, explained Samir Parekh, MBBS.

“We are moving from an era where we looked at myeloma under the microscope and thought of it as one disease. With these resolution techniques like next-generation sequencing, we are able to understand the genomics better. We have found most patients have 4 or 5 different clones of disease that all behave differently with chemotherapy and need to be tracked to understand how to treat patients better,” said Parekh, an associate professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai Hospital.

“In the future, every patient should have the tumor examined with genomics, in addition to having the pathology examined under a microscope,” added Parekh.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x